ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2L

Effect of Denosumab Compared with Risedronate in Glucocorticoid-Treated Individuals: Results from the 12-Month Primary Analysis of a Randomized, Double-Blind, Active-Controlled Study

K Saag1, RB Wagman2, P Geusens3, JD Adachi4, O Messina5, R Emkey6, R Chapurlat7, NS Daizadeh2, N Pannacciulli2 and WF Lems8, 1University of Alabama at Birmingham, Birmingham, AL, USA, Birmingham, AL, 2Amgen Inc., Thousand Oaks, CA, 3Maastricht University, Maastricht, Netherlands, 4McMaster University, Hamilton, ON, Canada, 5Cosme Argerich Hospital, Buenos Aires, Argentina, 6Emkey Arthritis & Osteoporosis Clinic, Wyomissing, PA, 7Hôpital Edouard Herriot, Lyon, France, 8VU University Medical Centre, Amsterdam, Netherlands

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: October 19, 2016

Keywords: Bone density, denosumab, glucocorticoids and osteoporosis, Late-Breaking 2016

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 15, 2016

Session Title: ACR Late-breaking Abstract Session

Session Type: ACR Late-breaking Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Glucocorticoid (GC)-induced osteoporosis (GIOP) remains the most common secondary cause of osteoporosis. Despite approved therapies, many subjects do not receive GIOP prevention or treatment. There is increased RANKL and decreased osteoprotegerin (OPG) expression in GIOP. Denosumab (DMAb) is a monoclonal antibody to RANKL. This study was designed to assess the safety and efficacy of DMAb compared with risedronate (RIS) in GC-treated individuals, in whom treatment guidelines advocate a GIOP intervention.

Methods: This was a phase 3, randomized, double-blind, active-controlled study to evaluate DMAb vs. RIS in GC-treated individuals for 24 mos. Eligible subjects were women and men ≥18 yrs receiving GC therapy at a dose ≥7.5 mg prednisone daily or its equivalent for ≥3 mos or <3 mos prior to screening (GC-continuing [GC-C] and GC-initiating [GC-I], respectively). All subjects <50 yrs were required to have a history of osteoporotic fracture. GC-C subjects ≥50 yrs were required to have a lumbar spine (LS), total hip (TH), or femoral neck bone mineral density (BMD) T‑score ≤‒2.0; or a T-score ≤‒1.0 with a history of fracture. Subjects were randomized 1:1 to SC DMAb 60 mg every 6 mos or oral RIS 5 mg daily for 24 mos. Subjects were to receive daily calcium (≥1000 mg) and vitamin D (≥800 IU) supplementation. The primary objective was to demonstrate in the GC-C and GC-I subpopulations separately that DMAb was not inferior to RIS with respect to percentage change from baseline in LS BMD at 12 mos. Secondary objectives were to assess superiority of DMAb over RIS with respect to percentage change from baseline in LS and TH BMD at 12 mos. The study remains blinded and is ongoing.

Results: A total of 795 subjects (505 GC-C and 290 GC-I) enrolled in the study. Baseline characteristics were balanced between treatment groups (Table). Non-inferiority and superiority with DMAb were demonstrated for both the GC-C and GC-I subpopulations, due to significantly greater gains in BMD compared with RIS at the LS and TH in both subpopulations (Figure). The incidences of adverse events (AEs) and serious AEs, including serious AEs of infection, as well as fracture, were similar between treatment groups and consistent with the known safety profile of DMAb.  

Conclusion: DMAb significantly increased BMD more than RIS at the spine and hip at 12 months. The overall safety profile was similar between treatment groups. DMAb has the potential to become another treatment option for patients newly initiating or continuing GC who are at risk for fracture.

   

 


Disclosure: K. Saag, Amgen, Merck, 5,Amgen, Merck, 2; R. Wagman, Amgen, 1,Amgen, 3; P. Geusens, Pfizer, Abbott, Lilly, Amgen, MSD, Will, Roche, UCB, BMS, Novartis, 9,Pfizer, Abbott, Lilly, Amgen, MSD, Will, Roche, UCB, BMS, Novartis, 9,Pfizer, Abbott, Lilly, Amgen, MSD, Will, Roche, UCB, BMS, Novartis, 9; J. Adachi, Amgen, Eli Lilly, Merck, Pfizer, 2,Amgen, Eli Lilly, Merck, 5,International Osteoporosis Foundation,, 6,Amgen, Eli Lilly, 8; O. Messina, GSK, Amgen, 2; R. Emkey, Amgen, 8; R. Chapurlat, Amgen, Merck, Chugai, 2,Amgen, Lilly, BMS, Abbvie, Pfizer, Chugai, UCB, 5; N. Daizadeh, Amgen Inc., 1,Amgen Inc., 3; N. Pannacciulli, Amgen Inc., 1,Amgen Inc., 3; W. Lems, Eli Lilly, Amgen, Novartis, MSD, 9,Eli Lilly, Amgen, Novartis, MSD, 9.

To cite this abstract in AMA style:

Saag K, Wagman R, Geusens P, Adachi J, Messina O, Emkey R, Chapurlat R, Daizadeh N, Pannacciulli N, Lems W. Effect of Denosumab Compared with Risedronate in Glucocorticoid-Treated Individuals: Results from the 12-Month Primary Analysis of a Randomized, Double-Blind, Active-Controlled Study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/effect-of-denosumab-compared-with-risedronate-in-glucocorticoid-treated-individuals-results-from-the-12-month-primary-analysis-of-a-randomized-double-blind-active-controlled-study/. Accessed January 25, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-denosumab-compared-with-risedronate-in-glucocorticoid-treated-individuals-results-from-the-12-month-primary-analysis-of-a-randomized-double-blind-active-controlled-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.